| 1/3 | US=47 / Câncer Yap TA, Molife LR, Bono JS. CDK inhibitors as anticancer agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 135-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DE CDK; AGENTES ANTICANCERIGENOS; CICLO CELULAR; CICLINA DEPENDENTE DE QUINASE; CICLINA; INIBIDOR; FLAVOPIRIDOL; UCN-01; E7070; SELICICLIB; BMS 387032; ZD 304709 |
| 2/3 | US=92 / Biol/Mol Maclean KH, Cleveland JL. DNA damage response, signalling pathways, and tumorigenesis: interactions between Myc- and cyclin-dependent kinase inhibitors in cancer. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 223-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9. |
| 3/3 | US=14 / Urologia Cote RJ, Lerner SP, Datar RH. Bladder and upper tract cancer: molecula biology and prognostic markers in bladder cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM. Comprehensive textbook of genitourinary oncology. 3ª ed. Philadelphia: Lippincott Williams & Wilkins, 2006. p. 385-401. ISBN 978-0-7817-4984-0. BEXIGA; CANCER DO TRATO SUPERIOR; BIOLOGIA MOLECULAR; MARCADORES PROGNOSTICOS; CANCER DE BEXIGA; VIA P53; GENE RETINOBLASTOMA; CICLINAS; QUINASES DEPENDENTES DA CICLINA; INIBIDORES DE CDK; ANGIOGENESE; RECEPTORES DO FATOR DE CRESCIMENTO; METILACAO DO DNA |